Gapping down
In reaction to disappointing earnings/guidance/SSS: THOR -26.4%, ELON -17%, BWC -12.6%, GEOS -9.5%, RNDY -9.5%, ANAD -9.1%, IO -8.4%, CSOD -8.2%, COUP -7.6%, TXTR -6.6%, OSUR -6%, TNGO -5.4%, ATML -5.2%, ATRS -5.2%, FTK -5.1%, ZEUS -4.9%, PHMD -4.7%, ERII -4.6%, CLDX -4.5%, ZU -4.5%, SD -4.5%, NVAX -4.1%, GPOR -3.9%, IXYS -3.9%, DVAX-3.9%, DRTX -3.7%, WIN -3.5%, CPA -3.3%, EVC -3.2%, NIHD -3.2%, BDBD -3%, CECE -3%, LAMR -3%, RDUS -2.8%, SABR -2.8%, IDCC -2.7%, FRED -2.6%, ACAS -2.4%, GMCR -2.2%, TSE -2.2%, SRPT -2%, MWE -1.9%, DSCI -1.9%, AUXL -1.8%, HIL -1.6%, MYL -1.6%, HRC -1.6%, YY -1.5%, CXW -1.5%, PRSC -1.5%, TOPS -1.5%, AGYS -1.4%, CPE -1.3%, LPI -1.3%, PHX-1.3%, CGI -1.1%, NVTL -1.1%, CTB -1%, MPEL -1%, COST -1%.
Select metals/mining stocks trading lower: TC -2.2%, AU -1.5%, AU -1.5%, HL -1.2%, HL -1.2%, IAG -1.1%, HMY -1%, BHP -0.5%, MT -0.4%.
Other news: NYMX -8% (Paul Averback sold in a private transaction for financial planning purposes 470,600 common shares of NYMX for a total consideration of $2.4 mln), UMPQ -3.5% (announces secondary offering of 15 mln shares held by Thomas H. Lee Partners and Warburg Pincus), SHPG -1.8% (still checking), PT -1.5% (still checking), YY -1.5% (Shanghai -1.3% overnight), EBS-1.3% (submits Biologics license application to FDA for Anthrax Immune Globulin Intravenous), ASTM -0.9% (filed for a $20 mln common stock offering), RSPP -0.8% (announces pricing of 10 mln shares of common stock offering at $25.65/share).
Analyst comments: NUS -0.6% (downgraded to Neutral from Overweight at JP Morgan), AET -0.6% (downgraded to Neutral from Buy at Goldman), UNH -0.6% (removed from Conviction Buy list at Goldman), PERI -0.5% (downgraded to Hold from Buy at Needham), VOD -0.4% (downgraded to Mkt Perform from Outperform at Raymond James).
In reaction to disappointing earnings/guidance/SSS: THOR -26.4%, ELON -17%, BWC -12.6%, GEOS -9.5%, RNDY -9.5%, ANAD -9.1%, IO -8.4%, CSOD -8.2%, COUP -7.6%, TXTR -6.6%, OSUR -6%, TNGO -5.4%, ATML -5.2%, ATRS -5.2%, FTK -5.1%, ZEUS -4.9%, PHMD -4.7%, ERII -4.6%, CLDX -4.5%, ZU -4.5%, SD -4.5%, NVAX -4.1%, GPOR -3.9%, IXYS -3.9%, DVAX-3.9%, DRTX -3.7%, WIN -3.5%, CPA -3.3%, EVC -3.2%, NIHD -3.2%, BDBD -3%, CECE -3%, LAMR -3%, RDUS -2.8%, SABR -2.8%, IDCC -2.7%, FRED -2.6%, ACAS -2.4%, GMCR -2.2%, TSE -2.2%, SRPT -2%, MWE -1.9%, DSCI -1.9%, AUXL -1.8%, HIL -1.6%, MYL -1.6%, HRC -1.6%, YY -1.5%, CXW -1.5%, PRSC -1.5%, TOPS -1.5%, AGYS -1.4%, CPE -1.3%, LPI -1.3%, PHX-1.3%, CGI -1.1%, NVTL -1.1%, CTB -1%, MPEL -1%, COST -1%.
Select metals/mining stocks trading lower: TC -2.2%, AU -1.5%, AU -1.5%, HL -1.2%, HL -1.2%, IAG -1.1%, HMY -1%, BHP -0.5%, MT -0.4%.
Other news: NYMX -8% (Paul Averback sold in a private transaction for financial planning purposes 470,600 common shares of NYMX for a total consideration of $2.4 mln), UMPQ -3.5% (announces secondary offering of 15 mln shares held by Thomas H. Lee Partners and Warburg Pincus), SHPG -1.8% (still checking), PT -1.5% (still checking), YY -1.5% (Shanghai -1.3% overnight), EBS-1.3% (submits Biologics license application to FDA for Anthrax Immune Globulin Intravenous), ASTM -0.9% (filed for a $20 mln common stock offering), RSPP -0.8% (announces pricing of 10 mln shares of common stock offering at $25.65/share).
Analyst comments: NUS -0.6% (downgraded to Neutral from Overweight at JP Morgan), AET -0.6% (downgraded to Neutral from Buy at Goldman), UNH -0.6% (removed from Conviction Buy list at Goldman), PERI -0.5% (downgraded to Hold from Buy at Needham), VOD -0.4% (downgraded to Mkt Perform from Outperform at Raymond James).